









Markets
/
Stocks
/
nasdaq-lixt
/

Lixte Biotechnology Holdings Inc

LIXT

5.450USD

+0.030+0.55%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

15.03MMarket Cap

LossP/E TTM



Lixte Biotechnology Holdings Inc

5.450

+0.030+0.55%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

223 / 506

Overall Ranking

358 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Lixte Biotechnology Holdings, Inc. is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers. The Company encompasses that inhibitors of protein phosphatases have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. It is focused on development activities of its LB-100 series of drugs. The LB-100 series have activity against a broad spectrum of common and rarer human cancers in cell culture systems. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue.

Undervalued

The company’s latest PE is -4.24, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 811.70K shares, decreasing 2.96% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 5.38K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.76.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 7.00, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.00

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.20

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -4.22, which is -78.35% below the recent high of -0.91 and 66.13% above the recent low of -1.43.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 223/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.03.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 8.93, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 6.76 and the support level at 3.58, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.93

Change

0.01

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.147

Buy

RSI(14)

61.956

Neutral

STOCH(KDJ)(9,3,3)

61.648

Neutral

ATR(14)

0.595

High Vlolatility

CCI(14)

41.668

Neutral

Williams %R

36.177

Buy

TRIX(12,20)

1.642

Sell

StochRSI(14)

6.828

Oversold

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

5.566

Sell

MA10

5.319

Buy

MA20

4.646

Buy

MA50

4.312

Buy

MA100

2.849

Buy

MA200

2.292

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 29.28%, representing a quarter-over-quarter decrease of 15.44%. The largest institutional shareholder is The Vanguard, holding a total of 5.38K shares, representing 0.12% of shares outstanding, with 49.09% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Kovach (John S)

154.02K

John and Barbara Kovach 2015 Trust

133.33K

Orca Capital GmbH

120.01K

Arthur and Jane Riggs 1990 Irrevocable Trust

101.83K

Hightower Advisors, LLC

99.43K

Intracoastal Capital, L.L.C.

42.00K

Bernards (Rene)

25.00K

Ethos Financial Group, LLC

24.81K

Geode Capital Management, L.L.C.

23.04K

+36.61%

Krinsky (Glenn L)

14.17K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.05, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.50. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.